In addition, metformin has an additional benefit of inhibiting the mammalian target of rapamycin (mTOR) [74], which is activated in patients with IBD and may be responsible for triggering the inflammatory process in IBD [82]. Here, MTOR is linked to inflammatory bowel disease.